⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15870986 | 0.72 | HDAC8 (0.39) | — | |
| SCHEMBL17507196 | 0.69 | — | — | |
| SCHEMBL195035 | 0.67 | — | — | |
| SCHEMBL28061488 | 0.67 | CLK4 (0.38) | — | |
| SCHEMBL151679 | 0.67 | — | — | |
| SCHEMBL1201044 | 0.67 | — | — | |
| SCHEMBL1324980 | 0.67 | — | — | |
| SCHEMBL2852858 | 0.67 | — | — | |
| SCHEMBL206132 | 0.65 | — | — | |
| SCHEMBL3706470 | 0.65 | GRM5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | claimed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | claimed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | claimed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | claimed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | claimed |
| EP-2694061-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | Société Splicos (FR) | 2014-02-12 | — | — | EP | claimed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | claimed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | claimed |
| US-5468857-A | Phenylmethoxypropenoic esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-11-21 | — | — | US | claimed |
| US-5334748-A | A methyl 2-aryl heterofunctional phenoxyphenyl-3-methoxy-propenoate compound; treating the plant diseases | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-08-02 | — | — | US | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| EP-0370629-A1 | Fungicides | ZENECA LIMITED (GB) | 1990-05-30 | — | — | EP | disclosed |
| EP-0312243-A2 | Methyl 2-[2-(3-substituted phenoxy)pyridin-3-yl]-3-methoxypropenoatesand their use as fungicides | ZENECA LIMITED (GB) | 1989-04-19 | — | — | EP | disclosed |
| EP-0307103-A2 | Fungicides | ZENECA LIMITED (GB) | 1989-03-15 | — | — | EP | disclosed |
| EP-0278595-A2 | Fungicides | ZENECA LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |